R&D Parexel: Flawless execution, policy shifts & patient-centric... Parexel's Paul Bridges & Charlotte Moser discuss Europe's biotech sector in the face of an innovation cliff.
Oncology Citius’ Leonard Mazur talks targeted immune therapy for CTCL Leonard Mazur, CEO and Chairman of Citius Pharmaceuticals, discusses the launch of its first FDA-approved drug, Lymphir, for CTCL.
Oncology Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.
Patients Biosimilars & patient access independent of geographies or s... Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.
Patients Towards a healthier world: Momentum in UK health system tran... In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Lee-Ann Farrell, Head of National Programmes at Johnson & Johnson.
Digital Trustworthy and novel AI in clinical trial planning, with Kr... Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.